Freedom from Cancer Startup Challenge
  • Home
  • Winners
  • Overview
    • Key Dates
    • Phase 0 - Enter Challenge
    • Phase 1 - Elevator Speech
    • Phase 2 - Business Plan
    • Phase 3 - Start-up
  • Mavens
    • Ambassadors
    • Apply as Maven
  • About Us
    • Contact Us
    • Testimonials
    • News
    • Blog
  • Home
  • Winners
  • Overview
    • Key Dates
    • Phase 0 - Enter Challenge
    • Phase 1 - Elevator Speech
    • Phase 2 - Business Plan
    • Phase 3 - Start-up
  • Mavens
    • Ambassadors
    • Apply as Maven
  • About Us
    • Contact Us
    • Testimonials
    • News
    • Blog
Search by typing & pressing enter

YOUR CART

RETURN TO ALL INVENTIONS LIST
RETURN TO THERAPEUTICS ​LIST
Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject
Patent Number: US9364535

Executive Summary:
  • Invention Type: Therapeutic
  • Patent Status: Issued (Grant date: 2016-06-14)
  • Patent Link: https://patents.google.com/patent/US9364535
  • Research Institute: University of California, Berkeley
  • Disease Focus: Corneal transplantations
  • Basis of Invention: Inhibitors blocking VEGF receptors and integrin receptor are potent inhibitors not only of inflammatory corneal hemangiogenesis, but also lymphangiogenesis in vivo
  • How it works: Administering to the subject an effective amount of a first antagonist for a tyrosine kinase receptor and an effective amount of a second antagonist for an integrin receptor
  • Lead Challenge Inventor: Inhibitors that have been developed against lymphangiogenic growth factors and their receptors
  • Inventors: Chen; Lu (Berkeley, CA)
  • Development Stage: in vivo data (mice), preclinical
  • Novelty: Combination of chemicals used is novel (in the case of corneal transplantations)
  • Clinical Applications: Corneal transplantations

General Description:
This invention provides a novel method of modulating the occurrence of lymphangiogenesis in a subject by administering to the subject an amount of: a first antagonist for VEGFR-3, wherein the first antagonist is a neutralizing antibody or binding fragment thereof that specifically binds to VEGFR-3; and a second antagonist for VLA-1, wherein the second antagonist is a neutralizing antibody or binding fragment thereof that specifically binds to VLA-1; and has been shown to be effective to reduce the occurrence of lymphangiogenesis in a corneal transplant in the subject having a high risk of rejection.

Strengths:
  • The combination of inhibitors used is new

Weaknesses:
  • Has not been tested in humans yet

Patent Status:
  • Priority date:  2012-08-15
  • Filing date:  2013-08-14
  • Publication date: 2016-06-14
  • Grant date: 2016-06-14

Inventor Bio:
Lu Chen
https://optometry.berkeley.edu/people/lu-chen-md-phd/
Powered by Create your own unique website with customizable templates.